NeuroOne reports record $4.5 million purchase order and preliminary Q4 revenue growth

NeuroOne Medical Technologies Corporation disclosed on October 5, 2026 that it secured a $4.5 million product purchase order in September 2026, the largest in the company's history.¹ Of that order, about $1.0 million shipped in September 2026, and the company expects to ship the remaining $3.6 million starting in fiscal 2027's first quarter and continuing into the second quarter, pending manufacturing and delivery timing.¹

With this new order, total open purchase orders for shipments through the first quarter of fiscal 2027 rose to $5.4 million as of September 30, 2026.¹ The company said this gives it greater visibility into expected product shipments, cash flow and revenue as it enters fiscal 2027.¹

CEO Dave Rosa said product orders rose 24.2% in fiscal 2026 compared with fiscal 2025.¹ He added that the company sees further growth ahead from commercialization of its trigeminal neuralgia system, international market expansion, and advancement of its drug delivery platform.¹

On the financial side, NeuroOne said it anticipates fourth-quarter fiscal 2026 product revenue near $3.8 million, up 38.4% from about $2.7 million a year earlier.¹ For the full year, the company projected revenue of approximately $10.5 million, a 15.6% increase that reaches the top end of its prior guidance range of $9.2 million to $10.5 million.¹

The company said full financial results tied to its fiscal year-end will come alongside its upcoming annual filing with securities regulators, expected in December 2026. NeuroOne cautioned that these preliminary figures are unaudited and subject to adjustment, and that investors should not draw conclusions beyond what has been disclosed.¹